MapLight Therapeutics, Inc Common Stock
Yahoo Finance • 4 days ago
Stocks Settle Mixed as AI Angst Offsets Easing Geopolitical Tensions
The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.02%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.51%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.32%. September E-mini S&P futures (ESU26) rose +0.02%, and S... Full story
Yahoo Finance • 5 days ago
Top Midday Decliners
MapLight Therapeutics' (MPLT) shares tumbled 68% even after the company said its phase 2 trial of ML PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 5 days ago
Stocks Fall from Early Highs as Chipmakers Retreat
The S&P 500 Index ($SPX) (SPY) today is up +0.11%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.54%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.46%. September E-mini S&P futures (ESU26) are up +0.11%, and September E-min... Full story
Yahoo Finance • 5 days ago
Stocks making the biggest moves midday: ASML, SK Hynix, SAP, Forte Bio, Brown-Forman & more
Check out some of the companies making the biggest moves midday: ASML — The maker of semiconductor manufacturing equipment slid 8%. China began mass production of domestically made deep ultraviolet chipmaking tools, The Information reporte... Full story
Yahoo Finance • 5 days ago
Stocks Rally as Middle East Tensions Ease
The S&P 500 Index ($SPX) (SPY) today is up +0.65%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.08%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.56%. September E-mini S&P futures (ESU26) are up +0.65%, and September E-mini... Full story
Yahoo Finance • 5 days ago
MapLight Reports Results From Phase 2 ZEPHYR Trial Of ML-007C-MA; Stock Down More Than 60%
(RTTNews) - MapLight Therapeutics (MPLT) announced positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA in adults with an acute exacerbation of schizophrenia. The trial met its primary endpoint, with the 210/3 mg tw... Full story
Yahoo Finance • last month
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. MapLight Therapeutics, Inc. (NASDAQ:MPLT) is one of the best biotech stocks on this list. TheFly reported on June 24 that Raymond James initiated cove... Full story
Yahoo Finance • last month
MapLight's ML-004 Misses Phase 2 Endpoint But Shows Irritability Signal In Adolescents
(RTTNews) - MapLight Therapeutics, Inc. (MPLT) announced topline results from its Phase 2 IRIS study evaluating ML-004 in patients with autism spectrum disorder (ASD). The trial did not meet its primary endpoint measuring improvement in so... Full story
Yahoo Finance • last month
Pre-Market Movers: TNON, ADTX, LNAI See Sharp Moves
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Pre-market movers give traders an early read on momentum, sentiment, and potential volatility for the trading day. Price swings before the opening bell... Full story
Yahoo Finance • 2 months ago
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
What happened According to a recent SEC filing, Nan Fung Group Holdings Ltd reduced its position in Oculis(NASDAQ:OCS) by 163,957 shares during the first quarter of 2026. The estimated value of the trade was $4.3 million, based on the qua... Full story
Yahoo Finance • 2 months ago
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
FCPM III Services B.V. disclosed a new position in Damora Therapeutics(NASDAQ:DMRA) as of March 31, 2026, acquiring 2,441,000 shares for an estimated $65.63 million based on quarterly average pricing. What happened According to a Securit... Full story
Yahoo Finance • 2 months ago
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
On May 15, 2026, FCPM III Services B.V. reported a sale of 818,460 shares of Dyne Therapeutics(NASDAQ:DYN), an estimated $14.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commis... Full story
Yahoo Finance • 3 months ago
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April
MapLight Therapeutics(NASDAQ:MPLT) Chief Administrative and Accounting Officer Jonathan Gillis disclosed the direct sale of 69,835 shares of common stock in multiple open-market transactions on April 27 and April 28, 2026, according to an... Full story
Yahoo Finance • 3 months ago
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data
Key Points An MPLT executive reported selling 3,316 shares directly on April 15, 2026, for a transaction value of approximately $88,000 at an average price of $26.61 per share. No indirect or derivative shares were involved in the transac... Full story
Yahoo Finance • 4 months ago
MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying
MapLight Therapeutics, Inc. (NASDAQ:MPLT) is one of the 8 Healthcare Stocks Insiders Are Buying. On April 8, 2026, Needham initiated coverage of MapLight Therapeutics, Inc. (NASDAQ:MPLT) with a Buy rating and a $37 price target. Needham s... Full story
Yahoo Finance • 8 months ago
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes
* MapLight Therapeutics (NASDAQ:MPLT [https://seekingalpha.com/symbol/MPLT]) has been added to the Russell 2000 Index and the broader Russell 3000 Index, effective at the open of U.S. equity markets on December 22, 2025, as part of the 2... Full story